

Nanologica Q4 2023 - Strong outlook for 2024

Redeye updates its view and outlook on Nanologica following the company's year-end report and announcement of a fully guaranteed rights issue. We make minor revisions to our estimates and adjust our valuation for the dilution, leading to a new fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Nanologica Q4 2023 - Strong outlook for 2024](#)